Annual Report 2023
Department of Musculoskeletal Oncology and Rehabilitation Medicine
Akira Kawai, Shintaro Iwata, Eisuke Kobayashi, Koichi Ogura, Shuhei Osaki, Suguru Fukushima, Tetsuya Sekita, Yu Toda, Shin Ishihara, Takaya Funada, Shudai Muramatsu
Introduction
Since 1962, our department has accumulated a vast array of clinical knowledge regarding musculoskeletal tumors in collaboration with radiologists and pathologists specializing in sarcomas, enabling us to offer well-organized treatment strategies to patients with various types of bone and soft tissue tumors. We have also conducted basic and clinical studies using accumulated clinical samples and data to establish novel diagnostic methods and therapeutic approaches for treating musculoskeletal tumors. In addition, we have emphasized clinical trials in three distinct but inseparable areas for bone and soft tissue tumors: surgery, chemotherapy, and radiation therapy.
The Team and What We Do
Our department consists of six staff doctors and five residents. Occasionally, several fellows from Japan and overseas join our group. Outpatient consultations are held every weekday. A constant number of over 25 patients are hospitalized for surgery, chemotherapy, or radiation therapy. Six to 10 major surgeries for musculoskeletal tumors are routinely performed every week. The number of surgeries in our department in FY2023 was 403, of which 186 were for primary malignant bone and soft tissue tumors (Table 1).
In collaboration with the Department of Plastic and Reconstructive Surgery, we conduct definitive tumor resection and reconstructive surgery for cases with extensive soft tissue defects or concomitant resection of critical neurovascular structures. In addition, we actively collaborate with other departments to perform complex surgeries that may be challenging to perform in other hospitals, such as combined sacral resection for radical resection of locally advanced rectal cancer (Department of Colorectal Surgery), retroperitoneal sarcoma surgery (Departments of Urology, Colorectal Surgery, Hepatobiliary and Pancreatic Surgery, and Gastric Surgery), and chest wall sarcomas (Departments of Thoracic Surgery and Breast Surgery).
Regarding chemotherapy, we provide perioperative adjuvant chemotherapy for osteosarcoma and soft-tissue sarcoma, and chemotherapy for advanced stage bone and soft-tissue malignancies in collaboration with the Departments of Medical Oncology and Pediatric Oncology.
We hold various cross-disciplinary conferences, including a sarcoma conference, a pediatric oncology joint conference, a medical oncology joint conference, a retroperitoneal sarcoma conference, a rehabilitation conference, and a bone metastasis conference.
Table 1. Number of surgeries in FY2023
Research Activities
In basic research, in collaboration with the Division of Rare Cancer Research, National Cancer Center Research Institute, we have generated many sarcoma tissue mouse xenografts and new sarcoma cell lines, and have also performed comprehensive analysis of sarcoma-specific gene mutations and gene expression.
In addition, the following studies are being conducted;
- Utilization of VR/XR technology in bone and soft tissue tumor surgery.
- Intraoperative visualization of invasive soft tissue sarcomas using specific enzyme-activated fluorescent probes
- External validation of PATHFx, a prognostic tool for patients with bone metastases
- Development of novel oncogene therapy for sarcoma using antigen-specific TCR rapid analysis technology (in collaboration with Tokyo Metropolitan Institute of Medical Science)
The number of original papers published in English by the Department in FY2023 was 15.
The research funds received in FY2023 were one MHLW Grants-in-Aid for Scientific Research, three Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, one Cancer Research and Development Fund, and three private research funds.
Clinical Trials
We have the most significant number of patients with malignant bone and soft tissue tumors in Japan and serve as a center for clinical research, including the JCOG trials. In FY2023, we participated in six single-center studies, 12 domestic multi-institutional collaborative studies, and five international collaborative studies. We also led four clinical trials and served as the secretariat of the JCOG-EORTC international study.
Education
We actively accept young physicians from universities nationwide, regardless of academic affiliation, and train human resources who will lead the treatment of bone and soft tissue tumors in Japan. In FY2023, five residents, including oncology residents and short-term residents, were accepted and trained in the diagnosis, surgery, and pharmacotherapy of bone and soft tissue tumors.
Young doctors who have completed the training program are guided to become bone and soft tissue oncology specialists (surgeon-scientists) with excellent research minds. They are also guided in clinical research from planning to implementation, conference presentations, and paper writing. In FY2023, many excellent achievements were made, including two National Cancer Center Alumni Association awards.
We encourage trainees to obtain various certifications during their training in the department, including certified oncologists. In FY2023, two trainees were certified as oncologists, three as bone and soft tissue oncologists by the Japanese Orthopaedic Association, and one as a specialist in the Japanese Society of Rehabilitation Medicine.
In FY2023, two trainees from overseas (from Pakistan and Taiwan) were accepted to observe surgery and receive clinical research guidance.
Future Prospects
To further improve the outcome of malignant bone and soft tissue tumors, we must continue to promote innovative approaches, including surgery using advanced technologies and the development of new drugs, as well as continuing to establish and disseminate standard treatments not only in Japan but also worldwide by conducting multicenter clinical studies led by our hospital.
List of papers published in 2023
Journal
1. Yamagata Y, Komiyama M, Iwata S. Clinical characteristics and management of primary retroperitoneal sarcoma: A literature review. Annals of gastroenterological surgery, 8:21-29, 2024
2. Kojima N, Kubo T, Mori T, Satomi K, Matsushita Y, Iwata S, Yatabe Y, Ichimura K, Kawai A, Ichikawa H, Yoshida A. Myxoid liposarcoma with nuclear pleomorphism: a clinicopathological and molecular study. Virchows Archiv, 484:71-81, 2024
3. Mori T, Kobayashi E, Sato Y, Takenaka S, Endo M, Nakamura T, Morii T, Yoshida Y, Ueda T, Kawano H, Kawai A. What Are the Complication Rates and Factors Associated With Total Femur Replacement After Tumor Resection? Findings From the Japanese Musculoskeletal Oncology Group. Clinical orthopaedics and related research, 482:702-712, 2024
4. Odate T, Satomi K, Kubo T, Matsushita Y, Ueno T, Kurose A, Shomori K, Nakai T, Watanabe R, Segawa K, Ohshika S, Miyake N, Kudo S, Shimoi T, Kobayashi E, Komiyama M, Yoshimoto S, Nakatani F, Kawai A, Yatabe Y, Kohsaka S, Ichimura K, Ichikawa H, Yoshida A. Inflammatory Rhabdomyoblastic Tumor: Clinicopathologic and Molecular Analysis of 13 Cases. Modern pathology, 37:100359, 2024
5. Iwata S. CORR Insights(R): Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing. Clinical orthopaedics and related research, 482:564-565, 2024
6. Tatsuno R, Ichikawa J, Komohara Y, Pan C, Kawasaki T, Enomoto A, Aoki K, Hayakawa K, Iwata S, Jubashi T, Haro H. Pivotal role of IL-8 derived from the interaction between osteosarcoma and tumor-associated macrophages in osteosarcoma growth and metastasis via the FAK pathway. Cell death & disease, 15:108, 2024
7. Aiba H, Kojima Y, Shimoi T, Sudo K, Yazaki S, Imai T, Yoshida A, Iwata S, Kobayashi E, Kawai A, Arakawa A, Ogawa C, Kimura H, Yonemori K. Incidence of skeletal-related events in patients with Ewing sarcoma: An observational retrospective study in Japan. Cancer medicine, 13:e7060, 2024
8. Toda Y, Kobayashi E, Kubota D, Miyakita Y, Narita Y, Kawai A. A retrospective analysis of the prognosis of Japanese patients with sarcoma brain metastasis. Cancer medicine, 12:9471-9481, 2023
9. Matsuzaki J, Kato K, Oono K, Tsuchiya N, Sudo K, Shimomura A, Tamura K, Shiino S, Kinoshita T, Daiko H, Wada T, Katai H, Ochiai H, Kanemitsu Y, Takamaru H, Abe S, Saito Y, Boku N, Kondo S, Ueno H, Okusaka T, Shimada K, Ohe Y, Asakura K, Yoshida Y, Watanabe SI, Asano N, Kawai A, Ohno M, Narita Y, Ishikawa M, Kato T, Fujimoto H, Niida S, Sakamoto H, Takizawa S, Akiba T, Okanohara D, Shiraishi K, Kohno T, Takeshita F, Nakagama H, Ota N, Ochiya T. Prediction of tissue-of-origin of early stage cancers using serum miRNomes. JNCI cancer spectrum, 7:pkac080, 2023
10. Hagiwara Y, Iwata S, Ogura K, Kawai A, Susa M, Morioka H, Hiruma T, Tsuda Y, Kawano H, Yonemoto T, Ishii T, Okazaki K. Clinical analysis of multimodal treatment for localized synovial sarcoma: A multicenter retrospective study. Journal of orthopaedic science, 28:261-266, 2023
11. Noh S, Nessim C, Keung EZ, Roland CL, Strauss D, Sivarajah G, Fiore M, Biasoni D, Cioffi SPB, Mehtsun W, Cananzi FCM, Sicoli F, Quagliuolo V, Chen J, Luo C, Gladdy RA, Swallow C, Johnston W, Ford SJ, Evenden C, Tirotta F, Almond M, Nguyen L, Rutkowski P, Krotewicz M, Pennacchioli E, Cardona K, Gamboa A, Hompes D, Renard M, Kollár A, Ryser CO, Vassos N, Raut CP, Fairweather M, Krakorova DA, Quildrian S, Perhavec A, Nizri E, Farma JM, Greco SH, Vincenzi B, Lopez JAG, Solerdecoll MS, Iwata S, Fukushima S, Kim T, Tolomeo F, Snow H, Howlett-Jansen Y, Tzanis D, Nikulin M, Gronchi A, Sicklick JK. Retrospective Analysis of Retroperitoneal-Abdominal-Pelvic Ganglioneuromas: An International Study by the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). Annals of surgery, 278:267-273, 2023
12. Makise N, Shimoi T, Sunami K, Aoyagi Y, Kobayashi H, Tanaka S, Kawai A, Yonemori K, Ushiku T, Yoshida A. Loss of H3K27 trimethylation in a distinct group of de-differentiated chordoma of the skull base. Histopathology, 82:420-430, 2023
13. Akiyama T, Yoshimatsu Y, Noguchi R, Sin Y, Tsuchiya R, Ono T, Sato C, Kojima N, Yoshida A, Kawai A, Ohtori S, Kondo T. Correction to: Establishment and characterization of NCC-MRT1-C1: a novel cell line of malignant rhabdoid tumor. Human cell, 36:491, 2023
14. Akiyama T, Yoshimatsu Y, Noguchi R, Sin Y, Tsuchiya R, Ono T, Fukushima S, Toda Y, Kojima N, Yoshida A, Ohtori S, Kawai A, Kondo T. Correction to: Establishment and characterization of NCC-GCTB5-C1: a novel cell line of giant cell tumor of bone. Human cell, 36:492, 2023
15. Akiyama T, Yoshimatsu Y, Noguchi R, Sin Y, Osaki J, Adachi Y, Ono T, Tsuchiya R, Sato C, Iwata S, Kojima N, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-PLPS2-C1: a novel cell line of pleomorphic liposarcoma. Human cell, 36:468-475, 2023
16. Kamio S, Matsumoto M, Nakamura M, Kawai A, Kikuta K. Epidemiologic Survey of Myxofibrosarcoma Using Data from the Bone and Soft Tissue Tumor Registry in Japan. Annals of surgical oncology, 30:3074-3081, 2023
17. Toda Y, Ishihara S, Kawai A, Yoshida A. Blue lacy matrix in giant cell tumour of bone with or without denosumab therapy. Virchows Archiv, 483:125-129, 2023
18. Kobayashi H, Zhang L, Okajima K, Hirai T, Tsuda Y, Ikegami M, Kawai A, Tanaka S. Role of perioperative chemotherapy and radiotherapy for localized high-grade malignant peripheral nerve sheath tumor at the extremities and trunk wall: a population-based cohort study. Japanese journal of clinical oncology, 53:138-145, 2023
19. Stacchiotti S, Dürr HR, Schaefer IM, Woertler K, Haas R, Trama A, Caraceni A, Bajpai J, Baldi GG, Bernthal N, Blay JY, Boye K, Broto JM, Chen WT, Dei Tos PA, Desai J, Emhofer S, Eriksson M, Gronchi A, Gelderblom H, Hardes J, Hartmann W, Healey J, Italiano A, Jones RL, Kawai A, Leithner A, Loong H, Mascard E, Morosi C, Otten N, Palmerini E, Patel SR, Reichardt P, Rubin B, Rutkowski P, Sangalli C, Schuster K, Seddon BM, Shkodra M, Staals EL, Tap W, van de Rijn M, van Langevelde K, Vanhoenacker FMM, Wagner A, Wiltink L, Stern S, Van de Sande VM, Bauer S. Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts. Cancer treatment reviews, 112:102491, 2023
20. Satake T, Morizane C, Rikitake R, Higashi T, Okusaka T, Kawai A. Correction: The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry. Journal of gastroenterology, 58:184, 2023
21. Fukushima T, Watanabe N, Okita Y, Yokota S, Matsuoka A, Kojima K, Kurita D, Ishiyama K, Oguma J, Kawai A, Daiko H. The evaluation of the association between preoperative sarcopenia and postoperative pneumonia and factors for preoperative sarcopenia in patients undergoing thoracoscopic-laparoscopic esophagectomy for esophageal cancer. Surgery today, 53:782-790, 2023
22. Akiyama T, Yoshimatsu Y, Noguchi R, Sin Y, Osaki J, Ono T, Adachi Y, Tsuchiya R, Toda Y, Kobayashi E, Kojima N, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-DSM1-C1: a novel cell line derived from a patient with desmoid fibromatosis. Human cell, 36:847-853, 2023
23. Saito Y, Shimoi T, Iwata S, Maejima A, Abe K, Udagawa R, Yonemori K, Furukawa T, Wakao F. Impact of relative dose intensity of trabectedin with pegfilgrastim support: a single-centre retrospective study. Journal of chemotherapy (Florence, Italy), 35:737-744, 2023
24. Ishihara M, Nishida Y, Kitano S, Kawai A, Muraoka D, Momose F, Harada N, Miyahara Y, Seo N, Hattori H, Takada K, Emori M, Kakunaga S, Endo M, Matsumoto Y, Sasada T, Sato E, Yamada T, Matsumine A, Nagata Y, Watanabe T, Kageyama S, Shiku H. A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma. International journal of cancer, 152:2554-2566, 2023
25. Sugino H, Iwata S, Satomi K, Mori T, Nobusawa S, Nagashima T, Matsushita Y, Yatabe Y, Ichimura K, Kawai A, Yoshida A. Keratin-positive fibrotic extraskeletal myxoid chondrosarcoma: a close mimic of myoepithelial tumour. Histopathology, 82:937-945, 2023
26. Kojima N, Mori T, Motoi T, Kobayashi E, Yoshida M, Yatabe Y, Ichikawa H, Kawai A, Yonemori K, Antonescu CR, Yoshida A. Frequent CD30 Expression in an Emerging Group of Mesenchymal Tumors With NTRK, BRAF, RAF1, or RET Fusions. Modern pathology, 36:100083, 2023
27. Arikawa M, Akazawa S, Kageyama D, Kawai A, Miyamoto S. Soft Tissue Reconstruction Using the Free Forearm Fillet Flap in the Salvage of Forequarter Amputations for Recurrent Sarcoma: A Report of 2 Cases. Annals of plastic surgery, 90:334-338, 2023
28. Ishihara S, Ogura K, Maejima A, Shimoi T, Sudo K, Kojima Y, Fukushima S, Osaki S, Kobayashi E, Iwata S, Matsui Y, Yonemori K, Kawai A. Predictive value of peripheral blood markers in soft tissue sarcoma patients treated with eribulin. Japanese journal of clinical oncology, 53:494-500, 2023
29. Akahane K, Kasai S, Watanabe A, Kagami K, Komatsu C, Tamai M, Goi K, Oishi N, Yoshida A, Ogawa C, Kobayashi E, Inukai T. FGFR1 tyrosine kinase domain duplication in infantile soft tissue spindle cell tumor. Pediatric blood & cancer, e30354, 2023
30. Sugiyama M, Arakawa A, Shirakawa N, Tao K, Tanimura K, Nakajima M, Watanabe Y, Kumamoto T, Maniwa J, Yoneda A, Iwata S, Kobayashi E, Kawai A, Ogawa C. Safety and efficacy of multiple tyrosine kinase inhibitors in pediatric/adolescent and young adult patients with relapsed or refractory osteosarcomas: A single-institution retrospective analysis. Pediatric blood & cancer, 70:e30360, 2023
31. Aiba H, Kojima Y, Shimoi T, Sudo K, Yazaki S, Imai T, Yoshida A, Iwata S, Kobayashi E, Kawai A, Arakawa A, Ogawa C, Kimura H, Yonemori K. Clinical characteristics of primary cutaneous and subcutaneous Ewing sarcoma. Japanese journal of clinical oncology, 53:604-610, 2023
32. Ogata D, Namikawa K, Nakano E, Fujimori M, Uchitomi Y, Higashi T, Yamazaki N, Kawai A. Epidemiology of skin cancer based on Japan's National Cancer Registry 2016-2017. Cancer science, 114:2986-2992, 2023
33. Araki Y, Asano N, Yamamoto N, Hayashi K, Takeuchi A, Miwa S, Igarashi K, Higuchi T, Abe K, Taniguchi Y, Yonezawa H, Morinaga S, Asano Y, Yoshida T, Hanayama R, Matsuzaki J, Ochiya T, Kawai A, Tsuchiya H. A validation study for the utility of serum microRNA as a diagnostic and prognostic marker in patients with osteosarcoma. Oncology letters, 25:222, 2023
34. Zhang L, Iwata S, Saito M, Nakagawa M, Tsukushi S, Yoshida S, Gokita T, Ae K, Nakashima S, Watanuki M, Akiyama T. Hip Transposition Can Provide Early Walking Function After Periacetabular Tumor Resection: A Multicenter Study. Clinical orthopaedics and related research, 481:2406-2416, 2023
35. Tsuchiya R, Yoshimatsu Y, Noguchi R, Sin Y, Ono T, Akiyama T, Kosako H, Yoshida A, Ohtori S, Kawai A, Kondo T. Integrating analysis of proteome profile and drug screening identifies therapeutic potential of MET pathway for the treatment of malignant peripheral nerve sheath tumor. Expert review of proteomics, 20:109-119, 2023
36. Sano T, Setsu N, Kobayashi E, Kawai A. A Case of Encephalopathy Caused by Drug Interaction between Ifosfamide and Aprepitant. Yakugaku zasshi, 143:541-544, 2023
37. Toda Y, Iwata S, Kobayashi E, Ogura K, Osaki S, Fukushima S, Mawatari M, Kawai A. A vessel sealing system can help reduce the risk of postoperative complications after tumour resection in the medial thigh. Bone & joint open, 4:442-446, 2023
38. Ono T, Noguchi R, Yoshimatsu Y, Sin Y, Tsuchiya R, Akiyama T, Kojima N, Toda Y, Sato C, Fukushima S, Yoshida A, Kawai A, Kondo T. Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone. Human cell, 36:1804-1812, 2023
39. Watanabe S, Shimoi T, Nishikawa T, Kawachi A, Okuma HS, Tokura M, Yazaki S, Mizoguchi C, Arakaki M, Saito A, Kita S, Yamamoto K, Kojima Y, Sudo K, Noguchi E, Yoshida A, Kawai A, Fujiwara Y, Yonemori K. Lymphocyte-to-monocyte ratio as a prognostic and potential tumor microenvironment indicator in advanced soft tissue sarcoma treated with first-line doxorubicin therapy. Scientific reports, 13:10734, 2023
40. Morii T, Ogura K, Sato K, Kawai A. Incidence and risk of surgical site infection/periprosthetic joint infection in tumor endoprosthesis-data from the nationwide bone tumor registry in Japan. Journal of orthopaedic science, S0949-2658(23)00182-3, 2023
41. Kamoda H, Yonemoto T, Kawai A, Hiruma T, Iwata S, Nakayama R, Kobayashi H, Hirai T, Saito M, Ishii T. A multicentre retrospective study on extra-thoracic solitary fibrous tumour: preoperative MRI findings predict intraoperative findings and postoperative prognosis. Japanese journal of clinical oncology, 53:950-956, 2023
42. Akiyama T, Yoshimatsu Y, Noguchi R, Sin Y, Osaki J, Ono T, Adachi Y, Tsuchiya R, Toda Y, Ogura K, Kojima N, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-DFSP4-C1: a novel cell line from a patient with dermatofibrosarcoma protuberans having the fibrosarcomatous transformation. Human cell, 36:2187-2194, 2023
43. Fukushima T, Okita Y, Watanabe N, Yokota S, Nakano J, Tanaka Y, Kawai A. Progress in muscle strength of the reconstructed knee and quality of life of the patient after knee rotationplasty: A case report. Prosthetics and orthotics international, 47:651-654, 2023
44. Hirose T, Ikegami M, Kojima S, Yoshida A, Endo M, Shimada E, Kanahori M, Oyama R, Matsumoto Y, Nakashima Y, Kawai A, Mano H, Kohsaka S. Extensive analysis of 59 sarcoma-related fusion genes identified pazopanib as a potential inhibitor to COL1A1-PDGFB fusion gene. Cancer science, 114:4089-4100, 2023
45. Fukushima T, Okita Y, Watanabe N, Yokota S, Nakano J, Kawai A. Factors associated with physical function in patients after surgery for soft tissue sarcoma in the thigh. BMC musculoskeletal disorders, 24:661, 2023
46. Morii T, Sato K, Ogura K, Kawai A. Incidence and risk of infection in malignant soft tissue tumor resection: Data from the nationwide soft tissue tumor registry. Journal of orthopaedic science, S0949-2658(23)00211-7, 2023
47. Fukushima T, Okita Y, Watanabe N, Yokota S, Nakano J, Kawai A. Evaluation of clinical factors associated with early postoperative physical function and lower extremity functional impairment in patients with soft tissue sarcoma. Disability and rehabilitation, 1-6, 2023
48. Sekita T, Yoshida A, Kawai A, Ichikawa H, Kobayashi E. IDH-negative chondrosarcoma with metachronous dedifferentiation only in the metastatic site-A diagnostic pitfall. Genes, chromosomes & cancer, 62:755-760, 2023
49. Kawai A, Ishihara M, Nakamura T, Kitano S, Iwata S, Takada K, Emori M, Kato K, Endo M, Matsumoto Y, Kakunaga S, Sato E, Miyahara Y, Morino K, Tanaka S, Takahashi S, Matsuo F, Matsumine A, Kageyama S, Ueda T. Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial. Clinical cancer research, 29:5069-5078, 2023
50. Tsuchiya R, Kobayashi E, Fukushima S, Arikawa M, Ogura K, Iwata S, Akazawa S, Kawai A. Outcomes of Sling Procedure Using a Free Vascularized Fibular Graft After Resection of the Proximal Humerus. JB & JS open access, 8:e23.00044, 2023
51. Fujiwara T, Kunisada T, Nakata E, Mitsuhashi T, Ozaki T, Kawai A. Factors associated with survival in patients with clear cell sarcoma. The bone & joint journal, 105-B:1216-1225, 2023
52. Yoshimura N, Kariya R, Shimada M, Tateyama M, Matsunaga H, Shibata Y, Tanimura S, Takata K, Arima T, Kawakami J, Maeda K, Fukuma Y, Uragami M, Ideo K, Sugimoto K, Yonemitsu R, Matsushita K, Hisanaga S, Yugami M, Uehara Y, Masuda T, Nakamura T, Tokunaga T, Karasugi T, Sueyoshi T, Sato H, Iwakura Y, Araki K, Kobayashi E, Okada S, Miyamoto T. The IL-17-IL-17RA axis is required to promote osteosarcoma progression in mice. Scientific reports, 13:21572, 2023
53. Muramatsu S, Yoshida A, Kojima N, Mori T, Onuki H, Kawai A, Akazawa T, Kobayashi E. Case Report: Painful EWSR1::SMAD3-Positive fibroblastic tumor invading bone. JOS Case Reports, 2:188-191, 2023
54. Tsuchiya R, Kobayashi E, Tanzawa Y, Yoshida A, Ishii T, Kawai A. Functional scoliosis caused by painful leiomyoma of deep soft tissue: A case report. JOS Case Reports, 2:100-103, 2023